Clinical Profile Risk Factors and Outcome of HIV Infected Pulmonary Tuberculosis Patients by Ramalingam, A
CLINICAL PROFILE RISK FACTORS AND 
OUTCOME OF HIV INFECTED PULMONARY 
TUBERCULOSIS PATIENTS 
 
 
 
 
THIS DISSERTATION  
is submitted for 
MD DEGREE EXAMINATION 
BRANCH -I 
GENERAL MEDICINE 
GOVT. STANLEY MEDICAL COLLEGE AND HOSPITAL 
CHENNAI – 1. 
 
 
 
 
Submitted to  
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY  
CHENNAI 
 
MARCH - 2010 
 
 
ACKNOWLEDGEMENT 
 
 
I gratefully acknowledge and sincerely thank Dr.A.PRIYA, M.S., 
D.O. Dean Govt. Stanley Hospital and Dr. S.CHITRA, M.D., PhD., Dean 
Govt. Stanley Medical College, Chennai for granting me permission to 
utilize the facilities of the institution for my study. 
I am extremely grateful to our Head of the Department of Medicine, 
Prof Dr. S.RAMASAMY, M.D., Govt. Stanley Medical College and 
Hospital, Chennai for the guidance and encouragement given in fulfilling my 
work. 
I express my deep sense of gratitude to Prof Dr. RUCKMANI 
REDDY, M.D., for her valuable guidance at every stage of the study. 
I am grateful to my unit Assistant professors Dr. V.R. MOHAN 
RAO, M.D., and Dr. S. SARAVANA BABU, M.D., for their help in my 
research work. 
Finally I am extremely thankful to all my patients who cooperated in 
the study.  
CERTIFICATE 
 
 
This is to certify that the dissertation entitled “CLINICAL 
PROFILE RISK FACTORS AND OUTCOME OF HIV INFECTED 
PULMONARY TUBERCULOSIS PATIENTS” is the bonafide original 
work of Dr. A.RAMALINGAM, done by him under my guidance in partial 
fulfillment of the requirements for MD (General Medicine) branch I 
examination of The Tamilnadu Dr. M.G.R. Medical University to be held in 
March 2010. The period of post graduate study and training was from May 
2007 to February 2010. I forward this to the Tamil Nadu Dr. M.G.R. 
Medical University, Chennai, Tamil Nadu, India. 
 
 
 
 
Prof. Dr. S.RAMASAMY, M.D., THE DEAN 
Professor and Head Govt. Stanley Medical College  
Department of Medicine and Hospital 
Govt. Stanley Medical College, Chennai – 600 001. 
Chennai – 600 001. 
  
 
 
 
  
  
 
 
 
DECLARATION 
 
 
I Solemnly declare that the dissertation titled “CLINICAL 
PROFILE RISK FACTORS AND OUTCOME OF HIV INFECTED 
PULMONARY TUBERCULOSIS PATIENTS” was done by me at 
Stanley Medical College and Hospital during 2007-2009 under the guidance 
and supervision of Prof. RUCKMANI REDDY, M.D., This dissertation is 
submitted to THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY 
towards the partial fulfillment of requirements for the award of M.D. Degree 
(Branch-I) in General Medicine. 
 
 
 
 
 
 
Date : Dr. A. RAMALINGAM 
 
Chennai : 
  
 
 
 
 
 
 
 
 
 CONTENTS 
 
 
Sl.No Title Page No. 
1. INTRODUCTION 1 
2. AIM OF THE STUDY  25 
3. REVIEW OF LITERATURE 26 
4. METHODOLOGY  39 
5. RESULTS & ANALYSIS 41 
6. DISCUSSION 55 
7. CONCLUSION 60 
8. ANNEXURE  
9 PROFORMA 
9 BIBLIOGRAPHY 
9 MASTER CHART 
 
 
 
 
 1
INTRODUCTION 
 
Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) are 
leading causes of  infectious diseases related morbidity and mortality. While 
one-third of the global population is infected with mycobacterium 
tuberculosis (MTB), 33 million individuals are estimated to be living with 
HIV globally (Global HIV report UNAIDS 2008). Approximately 13-15 
million HIV infected individuals are estimated to have HIV-TB co-infection 
(Global TB report WHO 2008). Currently India is estimated to have 2.5 
million HIV infected individuals and it also harbours the largest number of 
TB cases in the world (Global TB report 2008). 
 
 Active TB is the commonest opportunistic infection amongst HIV 
infected patients and is the leading cause of death amongst these patients. TB 
is one of the most virulent opportunistic infections and it appears early in the 
course of the HIV infection than other opportunistic infections. As it is one 
of the first opportunistic infection to appear in HIV-infected people, TB may 
be one of the earlier signs of HIV infection. HIV specifically eliminates 
macrophages and CD4 cells that provide immunity against TB thereby fuels 
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the spread of TB. People with latent TB are increasingly becoming infected 
with HIV and many more develop active TB because HIV weakens their 
immune system. People who are co-infected with both HIV and latent TB 
have  greater risk for developing active TB disease and becoming infectious 
compared to people not infected with HIV. TB in HIV patients has different 
clinical presentation, hence it can be a diagnostic challenge. TB progresses 
faster in HIV-infected people. In early stage the presentations of TB in TB-
HIV co-infection is the same as HIV-negative but in late stages extra-
pulmonary and disseminated forms are more common. The treatment 
outcome is different and chances of relapse and resistance are also high. TB 
in HIV is more likely to be fatal if undiagnosed or left untreated. 
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TUBERCULOSIS(1) 
 
 Tuberculosis is caused by M. tuberculosis. It is a strict aerobe, 
obligate parasite. Because of its exceptionally high lipid content the 
organism is resistant to drying, alcohol, alkali, acids and some germicides. 
Due to its unusually long doubling time (12-18 hours), growth in culture is 
slow (3-8 wks). Tuberculosis is transmitted by the airborne route by droplet 
nuclei. Coughing, sneezing, spitting, singing and other respiratory 
maneuvers generate droplets nuclei. A bout of coughing produces up to 3500 
nuclei, as does speaking for 5 minutes in a normal tone. 
PATHOLOGY 
 Mycobacterium tuberculosis bacilli that reach the alveoli are ingested  
by alveolar macrophages. The essential pathology in tuberculosis is the 
production of the characteristic lesion, the tubercle, which is an avascular 
granuloma  composed of central zone containing giant cells, with or without 
caseation, a peripheral zone of lymphocytes and fibroblasts. Depending on 
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the time of infection and the type of responses, tuberculosis may be 
classified as primary and post-primary types. 
Primary infection results in the primary (Ghon’s) focus, which may be 
present in any lung zone. The primary complex, the ensuing lymphangitis 
and hilar lymphadenitis constitute the primary complex. Primary infection 
heals with or without calcification. Haematogenous spread probably occurs 
via the lymphatics in the majority of the infected subjects, resulting in the 
seeding of the tubercle bacilli to other parts of the lung as well as other 
organs. This stage of infection is usually clinically and radiographically 
silent. 
The infection is contained but not eradicated, since viable organism 
may lie dormant within the granulomas for years to decades. Individuals 
with this latent tuberculosis infection (LTBI) do not have active disease and 
cannot transmit the organism to others. However, reactivation of disease 
may occur if the host’s immune defenses are impaired. Approximately 10% 
of individuals with LTBI who are not treated will develop active 
tuberculosis in their life time and half of these cases occur in next two year, 
following primary infections. Upto 50% of HIV infected patients will 
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develop active tuberculosis within two years after infection with M. 
tuberculosis. Diverse condition such as gastrectomy, silicosis, diabetes 
mellitus, disorders associated with immunosuppression including HIV 
infection and acquired immunodeficiency syndrome (AIDS), corticosteroid, 
other immunosuppressant drug use, are associated with increased risk of 
reactivation of tuberculosis. 
In less than 10% of patients, the host immune response is inadequate 
and progressive primary tuberculosis develops. Reactivation of latent 
tuberculosis infection is the most frequent (90%) form of post-primary 
pulmonary tuberculosis. Reactivation pulmonary tuberculosis is most often 
seen in the upper lung zones  most frequently in the posterior segment of 
upper lobe or the apical segment of the lower lobe. The high ventilation-
perfusion ratio, with increased alveolar partial pressure of oxygen relative to 
other zones is believed to predispose the reactivation at these sites. 
Proliferation of tubercle bacilli in the caseous centre is followed by softening 
and liquefaction of the caseous material, which may discharge in to the 
bronchus with resultant cavity formation. The bacillary load is about 104 
bacilli per gram in the caseous tissue  and  upto 109 organisms may be found 
in single cavitary lesion. Rupture of caseous pulmonary focus into arterial 
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blood may result in military tuberculosis, with the formation of multiple 
millet sized (0.5-2mm) tuberculosis foci in the lung and various other organs 
of body. 
IMMUNOLOGY 
 The only specific immune mechanism effective is cell mediated type; 
humoral immunity appears to be non-protective. The key cell is activated 
CD4+  T-lymphocytes which can develop along two different paths, namely 
the Th1 or Th2 cells. Th1 dependent cytokines activate macrophages 
resulting in protective immunity and containment of infection. Th2 
cytokines induce delayed type hypersensitivity which produces tissue 
destruction and progressive disease. 
CLINICAL FEATURES 
Tuberculosis disease may manifest in to pulmonary and extra-
pulmonary forms.  Pulmonary tuberculosis, by far the most common form, 
can manifest as primary progressive primary and post-primary forms. 
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Primary Tuberculosis 
In the regions with high prevalence, primary tuberculosis is usually 
seen in children. It is manifested by the primary focus, the inflamed 
lymphatics and the enlarged regional lymph nodes. Majority of cases are 
asymptomatic, with the only evidence of infection being the development of 
positive tuberculin test three to six weeks after infection. Rarely primary 
infection may progress rapidly to active disease. This may involve local 
extension in to the lung parenchyma (often with cavitations and/or pleural 
effusion), systemic dissemination (military tuberculosis and tuberculosis 
meningitis) and local complications such as enlarged lymph nodes 
compressing bronchi, causing obstruction and subsequent segmental or lobar 
collapse, obstructive emphysema and bronchiectasis. 
Post-Primary Tuberculosis 
Early symptoms and signs of post-primary tuberculosis are often non-
specific and insidious, consisting of fever, night sweat, weight loss, 
anorexia, general malaise and weakness. Most patients develop a cough, 
which may be non-productive initially later being accompanied by purulent 
sputum are not infrequent and frank hemoptysis may occasionally occur. 
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Pleuritic chest pain some times develops in those with subpleural 
parenchymal lesions but can also result from muscle strain due to persistent 
coughing. On general physical examination there may be wasting, pallor, 
and digital clubbing. Respiratory system examination may sometimes be 
unremarkable. Usually, crepitations may be heard in the affected areas after 
coughing, bronchial breathing of different characters (tubular, cavernous and 
amphoric) may be audible depending on the extent of disease. 
Drug-Resistant Tuberculosis 
Multidrug resistant tuberculosis (MDR-TB) caused by 
Mycobacterium tuberculosis that is resistant to both  isoniazid and 
rifampicin with or without resistance to other durgs. Extensively drug-
resistant tuberculosis (XDR-TB) is defined as resistance to at least 
rifampicin and isoniazid (which is the definition of MDR-TB), in addition to 
any fluoroquinolone, and to at least one of the three following injectable 
drugs used in anti-TB treatment: capreomycin, kanamycin and amikacin, has 
emerged recently. XDR-TB is associated with a high mortality rate and 
along with MDR-TB it threatens to jeopardize global TB control. Incomplete 
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and inadequate treatment is the most important factor for MDR-TB and 
XDR-TB are manmade disasters. 
DIAGNOSIS 
Sputum Microscopy 
Diagnosis of tuberculosis is established by demonstrating acid-fast 
bacilli (AFB) on microscopic examination of at least two sputum smears 
through Ziel Nielson technique. Other staining methods include rhodamine-
auromine staining and fluorescence microscopy, a method that is faster and 
more sensitive. Sputum microscopy usually identifies only half of patients 
with pulmonary tuberculosis, as at least 10,000 organisms/ml of sputum are 
required to detect AFB. This is particularly relevant in persons with HIV 
infection in whom lung cavitations is less common, the yield of smear 
microscopy is low. 
Mycobacterial Culture 
Definitive diagnosis of pulmonary tuberculosis depends on the 
isolation and identification of M. tuberculosis in culture. Sputum 
mycobacterial culture is more sensitive (80%) than smear microscopy 
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(<50%) requiring less than 1000 AFB/ml for the diagnosis. In addition, it 
allows drug sensitivity testing and characterization of the isolates as drug 
sensitive or resistant. Various media are available for isolating tubercle 
bacilli. Lowenstein-Jensen egg medium and Kirchner’s broth both require up 
to six to eight weeks for documenting positive growth. 
Rapid Diagnosis 
Liquid media with radiometric growth detection systems (e.g., 
Bactec460) and the identification of isolates by nucleic acid probes or 
polymerase chain reaction (PCR) are also increasingly being used for rapid 
diagnosis of tuberculosis. 
Imaging 
Radiographic abnormities in primary pulmonary tuberculosis include 
small homogenous infiltrates with lymph node (hilar, paratracheal) 
enlargement and segmental atelectasis. Pleural effusion may be present, 
especially in adults, sometimes as the sole radiographic abnormality. 
Cavitation may be seen with progressive primary tuberculosis. Ghon 
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(calcified primary focus) and Ranke (calcified primary focus and hilar 
lymph nodes) complexes are evident in some patients. 
Reactivation tuberculosis is associated with various radiographic 
manifestations, including fibrocavitary apical disease, nodules and 
pneumonic infiltrates. The usual location is in the apical or posterior 
segments of upper lobes. In elderly and patients with immunocompromised 
status like diabetes, lower lobe infiltrates with or without pleural effusion is 
encountered with increased frequency. A military pattern (diffuse small, 
<2mm, nodular densities) can be seen with haematologic or lymphatic 
dissemination of the organism. Resolution of reactivation of tuberculosis 
leaves characteristic radiographic findings such as dense nodules in the 
pulmonary hila with or without obvious calcification, upper lobe 
fibronodular scarring and bronchiectasis with volume loss. Radiologically 
the extent of disease can be classified in to minimal, moderately advanced 
and far advanced tuberculosis. 
Tuberculin Skin Test 
In adults, especially in endemic areas, the tuberculin skin test (TST) is 
of limited value for diagnosis of tuberculosis disease due to low sensitivity 
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and specificity. TST also cannot distinguish between LTBI and active 
disease. In addition positive results are found in people who have been 
sensitised by non-tuberculous mycobacteria or bacilli Calmette-Guerin 
(BCG) vaccination. False-negative reaction is common in immuno 
suppressed patients and in patients with overwhelming tuberculosis. 
Interferon-γ Based Assays 
A significant recent development has been the availability of 
interferon-γ (IFN-γ) assays  based on the principle that T-cells of sensitized 
individuals produce IFN-γ when they re-encounter the antigens of 
M.tuberculosis. The IFN-γ assays are available in the enzyme linked 
immunosorbent assay (ELISA) and the enzyme-linked immunospot 
(ELISPOT) formats. These assays are not hampered by the limitations of 
TST and seem to have the potential to replace TST in future.  
Other Methods 
Serodiagnostic tests cannot reliably distinguish active tuberculosis 
from infection with M.tuberculosis. Molecular methods such as PCR are 
hindered by high sensitivity and false positivity. 
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MANAGEMENT 
The World Health Organisation (WHO) recommends directly 
observed treatment, short-course (DOTS) approach to control TB globally. 
DOTS strategy which aims at detecting atleast 70% of the existing cases of 
sputum smear-positive cases and curing at least 85% of these newly detected 
cases have been observed not only to ensure cure but also reduce the number 
of deaths due to TB. The Revised National Tuberculosis Control Programme 
(RNTCP) of India that now covers the whole country, has adopted the WHO 
recommended DOTS strategy for the control of TB. Recently, the 
International Standards for Tuberculosis Care (ISTC) has been published. 
The ISTC were developed to facilitate the effective engagement of all care 
providers, public as well as private in delivering high-quality care to 
patients. 
All treatment regimens have two phases, namely an initial intensive 
phase and a continuation phase. The initial intensive phase of treatment is 
designed to kill actively growing and semi- dormant bacilli and to shorter, 
duration of infectiousness, usually with rapid smear conversion (80-90%) by 
two to three months of treatment. The continuation phase eliminates most 
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residual bacilli and reduces treatment failure and relapse. Treatment can be 
given daily as well as thrice weekly and the treatment must be supervised. 
All treatment regimens must be in accordance to standards guidelines. 
All patients should be monitored for response to therapy, best judged 
in patients with pulmonary tuberculosis by followup sputum microscopy (2 
specimens), at least the time of completion of the initial phase of treatment 
(2 or 3 months), at five months and at end of treatment. Monitoring of 
progress of treatment can also be assessed clinically and radiologically, but 
they are less reliable. 
 If relapse occurs in spite of adequate supervised treatment, or after 
short course of regular treatment the patients should be treated category II 
treatment. MDR-TB and XDR-TB should be treated at specialised centers 
equipped with facilities for the treating these dangerous forms of 
tuberculosis. 
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 HUMAN IMMUNODEFICIENCY VIRUS(2)  
HIV belongs to the class Retroviruses and family Lentivirinae. Two types of 
HIV are recognised viz. HIV-1 and HIV-2. Both viruses have a nucleotide 
sequence homology of about 45% and differ in geographical distribution, 
biological and molecular characteristics and extent of transmissibility, 
though both lead to AIDS. However, HIV-2 has been found to be less 
virulent, less infective and has a longer asymptomatic phase than HIV-1. 
HIV-1 has three groups: HIV-1 major group (M) outlier group (O); and new 
group (N). HIV-1 major group can be further classified into subtypes or 
classes designated A through H, J and K. such subtypes have envelope gene 
sequences that vary by 20% or more between subtypes. The subtype C has 
been primarily reported in India. 
STRUCTURE OF VIRUS 
The virus comprises of an outer envelope consisting of a lipid bilayer 
with uniformly arranged 72 spikes or knobs of gp120 and gp41. The 
glycoprotein (gp) 120 protrudes out on the surface of the virus and gp41 is 
embedded in the lipid matrix. Interior to lipid bilayer are the matrix; internal 
capsular and nuclear capsid proteins. The core is a ‘cone’ shaped structure 
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(capsid) and contains two copies of single stranded RNA and viral enzymes 
reverse transcriptase, integrase and protease, all essential for viral replication 
and maturation. Surrounding the capsid is a layer of P17 core Gag protein, 
which is myristoylated. This P17 protein constitutes the matrix of the virion 
structure. It is vital for maintaining the integrity of viral particle. The size of 
HIVgenome is about 9.8 kb. HIV has structural and regulatory genes coding 
for structural and regulatory products, respectively. Structural genes direct 
the synthesis of physical components of the virus and are also responsible 
for viral size, shape, structural integrity and its compartmentalisation in host 
cell. The regulatory genes direct synthesis of proteins that effect the 
synthesis of viral components and viral replication. The pol. Env and gag are 
the structural genes while the enzymes are derived from the regulatory 
genes. 
The high variability of the virus accounts for drug resistance and 
evasion from immune response. This also poses problems for development 
of a successful vaccine. 
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REPLICATION CYCLE 
As the virus enters the blood stream, it binds to the CD4 cell receptor 
on T-lymphocytes via its outer gp 120 cover and enters the cellular 
cytoplasm, where it uncoats and shed its envelope, viral RNA and the unique 
enzyme, ‘reverse transcriptase’. This enzyme facilitates conversion of viral 
RNA into DNA, which is known as pro-viral DNA. The pro-viral DNA then 
creates a mirror image of itself and with the help of another enzyme called 
‘integrase’, unites with the host genome and becomes an integral part of the 
host cell. It then multiplies repeatedly and produces messenger RNA along 
with the multiplication of the nucleus of the host cell. The messenger RNA 
directs the host cell machinery to produce new viral particles, which form 
new virions with the helps of another enzyme known as ‘protease’. The 
small virions then bud out of the cell and infect other cells with CD4 
receptor. Thus, one infected cell becomes a factory producing large number 
of HIV viruses. During active stage of HIV infection, around one billion 
viruses are produced every day. 
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TRANSMISSION OF VIRUS 
The virus can be transmitted by following ways: unprotected sex with 
an infected person; use of unsterilised needles; transfusion of infected blood 
and blood products and from an infected mother to her child before, during 
or after birth.. The source of virus in the new born is multi-factoral. HIV 
infection can occur via amniotic fluid, genital secretions, maternal blood and 
also through the breast milk.  
NATURAL HISTORY OF HIV/AIDS 
Infection with HIV leads to a progressive impairment of cellular 
immune function, characterized by a gradual decline in peripheral blood 
CD4+ T-lymphocyte levels, which results in an increasing susceptibility to 
wide variety of opportunistic viral, bacterial, protozoal and fungal infections 
and to certain malignancies also. The course of the disease is marked by 
increasing levels of viral replication, emergence of more virulent viral 
strains and progressive destruction of immune system. However, the natural 
history of HIV infection can be changed with better diagnosis, ARV therapy 
and early treatment and prophylaxis of various opportunistic infections. 
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PROGRESSION OF HIV INFECTION 
Three dominant patterns of HIV disease progression have been 
described. Almost  80-90% of  HIV infected are ‘typical progressors’ with a 
median survival time of 10 years, approximately. About 5-10% of HIV 
infected individuals are rapid progressors’ with a median survival time of 3-
4 years approximately. About 7-10% of HIV infected individuals do not 
experience disease progression for an extended period of time and are called 
‘long-term non-progressors’ (LTNPs). 
PATHOGENESIS 
HIV is a polytrophic virus and can infect many cells of the immune 
system. These include CD4+ T cells, macrophages, dentritic cells, microglial 
cells and astrocytes in the brain and mucosal cells in the bowel. The CD4 
molecule is a major cellular receptor site for HIV. However, certain co-
receptors determine tropism for various cell types.  A homozygous delta-32 
mutation in the genes encoding for the CCR5 co- receptor is associated with 
resistance to infection. There is a role of endogenous cellular inhibitory 
factor (APOBEC 3G) in supporting viral replication. Certain viral genes 
(e.g.vif) inhibits the activity of APOBEC 3G leading to continued viral 
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replication. Other protective mechanisms including mucosal IgA 
neutralizing antibody response and high cytotoxic T lymphocytes (CTL) 
responses have been documented in some seronegative but exposed 
individuals. 
The virus exists in large number throughout the course of HIV 
infection. The half-life of HIV-1 in plasma appears to be only 1-2 days, and 
that of infectious virions is in the order of minutes.The rapid turnover of 
HIV provides the ideal mechanism for producing variants with mutations 
that confer drug resistance or permit escape from immunologic control of 
HIV infection. 
Apart from direct cytopathic effect of budding out from cell, 
numerous other mechanisms are known to contribute to HIV associated cell 
death. These include intracellular accumulation of viral extrachromosomal 
DNA, changes in cell membranes integrity by HIV envelope proteins, 
apoptosis (more common in uninfected CD4+ T cells) induced by various 
viral proteins and cytokine alteration, and superantigen induced up-
regulation of cell replication and inducing cell activation associated with 
apoptosis. 
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HIV pathogenesis involves three major clinical stages of infection: an 
early period during which high viral replication takes place, a persistent 
period during which virus is maintained at a lower threshold primarily by the 
immune system and symptomatic period during which viral replication 
reemerges and presages development of disease. 
Early period    
After viral entry, during the period  of primary viraemia there are 
large number of infected cells in the peripheral blood and high titres of 
infectious virus in the plasma and the lymphnodes (including the CD4 
effector cells in the intestinal lamina propria). This is reflected by p24 
antigenemia and  high plasma viral load. There is also dissemination of the 
virus into various compartments including the central nervous system. This 
robust virus replication is associated with a measurable decrease in the 
CD4+ T cell counts, reflecting an increased rate of destruction. During this 
initial CD4 cell depletion the precursors (CD4+central memory T cells) are 
relatively spared. These viral titres decrease dramatically as effective virus-
specific immunity develops in the host. Immunologic mechanisms 
contributing to initial control of viral replication include HIV specific 
 22
cytotoxic T-lymphocyte response, antibody-dependent cellular toxicity and 
HIV-specific CD4+T cell response. This results in stabilization of viral 
levels and CD4+ T cell counts at a ‘set-point’ for many years. This set-point 
is an independent predictor of prognosis, higher the set-point worse the 
prognosis. Resting memory CD4+ T cells occasionally become infected. 
These cells constitute the reservoir of latently infected cells, which can 
reseed the plasma with HIV when stimulated. Other latent reservoirs of HIV 
include the brain, genital organs (testes) and the kidney. All these reservoirs 
are established during early infection. Presence of HIV in these reservoirs is 
the main hurdle for achieving viral eradication. 
Persistent period 
Despite low level of viraemia, CD4 + T cell decline continues at a rate 
of 25-60 cells/year during chronic infection. Early in the course of infection, 
CD4+ memory cells are preferentially depleted but as the disease advances 
even the CD4+ native cells decline. Cellular destruction, diminished cellular 
production and cellular sequestration may all be important mechanisms for 
CD4+ T cell decline. In addition to CD4 + T cell loss, a dramatic increase in 
CD8 + T cell apoptosis has been noted, despite the fact that HIV does not 
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infect these cells. This is a common theme in HIV-induced immuno- and 
neuropathogensis.  
The immune system plays a considerable role in determining the viral 
set point and in delaying disease progression. Humoral and cellular immune 
responses to HIV is detected during this phase. Antibody levels against HIV 
are high but they have very weak neutralizing activity. CTL response 
(mediated by CD8+ T cells) inhibits viral replication by two mechanisms-
one, by direct killing of infected cells and second, by producing chemokines 
that inhibit viral replication. 
Symptomatic period 
Although the immune system can exert a potent responses against 
HIV, viraemia persists in the vast majority of untreated infected persons and 
disease progression occurs. CTL responses decline with time, coincident 
with progression due to immune exhaustion, lack of adequate T-helper cell 
function, immune escape, host genetic factors, viral reservoirs and defects in 
antigen-presenting cells. By the time the individual develops symptoms, 
CD4+ Tcells counts have usually dropped below 300/mm3 and the HIV in 
the blood and the lymph nodes has again risen to high levels.  
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1993 REVISED CLASSIFICATION SYSTEM FOR HIV INFECTION 
AND EXPANDED AIDS SURVEILLANCE CASE DEFINITION FOR 
ADOLESCENTS AND ADULTS 
             
 
CD4+ T Cell 
Categories 
(cells/µl) 
         A  
 
Asymptomatic,
Acute 
(Primary) 
HIV or PGL 
          B  
 
Symptomatic,
Not A or C 
Conditions 
          C  
 
AIDS 
Indicator 
Conditions 
>500 A1 B1 C1 
200 to 499 A2 B2 C2 
<200 A3 B3 C3 
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AIMS AND OBJECTIVES 
 
1. To study the clinical profile of pulmonary tuberculosis in HIV 
positive  patients. 
2. To analyse the risk factors and outcome of HIV/TB coinfection in 
North Chennai suburban population. 
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REVIEW OF LITERATURE 
HIV AND TB CO-INFECTION 
PATHOGENSIS  
 The life time risk for development of active TB in patients infected 
with TB is 10%. Immunosuppression associated with HIV infection 
amplifies this risk to 5-16% per year (3). The major feature of HIV induced 
immunosuppression is loss of the CD4+ helper cells that are important for 
regulation of cell mediated immunity. 
HIV infected patients have increased risk for acquisition of MTB, 
particularly the MDR/XDR organisms. After infection rapid progression to 
clinical disease (post-primary TB) has been documented and so is a high risk 
of reactivation of subclinical MTB infection (4). Finally TB can also occur as 
an immune reconstitution inflammatory syndrome (IRIS) described later in 
the review. 
Tuberculosis also impacts the course of HIV disease. High HIV viral 
loads and low CD4 counts have been documented in the setting of active 
TB(5). The consequence of up-regulation of viral replication results in 
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emergence of diverse HIV quasispecies. Patients with TB/HIV have higher 
mortality than those without TB even after matching for CD4 counts. 
CLINICAL FEATURES 
The clinical features of TB in HIV infection various according to the 
degree of immune-suppression. When CD4 Counts are high (>350/µl), the 
features are typical with granuloma formations, upper zone disease in the 
lungs and less frequent extra-pulmonary TB. However with higher degrees 
of immune suppression (CD4<350/µl), there is ineffective containment of  
MTB leading to disseminated disease, more frequent extra-pulmonary 
disease, impaired granuloma formation and atypical lung involvement (6).  
Clinical presentation of TB depends on the degree of immune-
supression. 
TB/HIV : CLINICAL FEATURES 
CD4>350 CD4<350 
• Classical features • Atypical features 
• Usually pulmonary • Usually EP, disseminated 
• Upper Zone, cavities • Lower Zones 
• ? Opportunistic • Opportunistic 
• Usually reactivation • Usually re-infection 
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Tuberculosis could be suspected in an HIV infected patient even when there 
are features that are not classically suggestive of diagnosis. For e.g. patients 
with unexplained weight loss, Fever of Unknown origin and severe anaemia 
/ leucopenia could be intensively investigated for TB. 
DIAGNOSIS 
The traditional methods of TB diagnosis may have lesser sensitivity in 
the context of HIV. An aggressive approach to get microbiological proof of 
diagnosis is needed in these settings. 
Radiology 
          As mentioned above HIV infected patients with respiratory TB have a 
tendency to have more commonly lower lobe involvements, less cavitations 
and frequently normal chest Xrays, particularly with advanced immune 
suppression (7). An HRCT thorax has higher sensitivity to pick up both 
pulmonary and extra-pulmonary disease (mediastinal nodes) that can suggest 
a TB diagnosis. 
Tuberculin test 
The tuberculin test has a lower sensitivity to detect latent TB amongst 
HIV infected patients (8). A lower cut-off of 5mm has been recommended in 
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situations where TB is non-endemic, although this also has limited value. 
Anergy associated with HIV infection may lead to false-ve TT(9). Infection 
with non-tuberculous mycobacteria and receipt of BCG vaccine may 
confound the interpretation of a positive TT. Positive TT is not an indication 
of active TB and thus has no role in this setting. 
Sputum smears 
The sensitivity of smear evaluation for AFB in the sputum is lower 
amongst HIV infected patients(10). In the context of patient not providing a 
sputum specimen, Broncho-alveloar lavage may increase the yield of finding 
AFB. However, if a patient has sputum smear negative, BAL does not 
increase the sensitivity for finding MTB. Alternative methods for sputum 
processing (concentration methods, short term bleach digestion) or AFB 
detection (immunofluroescence) may increase the sensitivity of detecting 
AFB. 
Alternative methods  
For assessing cell mediated immune response against MTB are the 
gamma-interferon assays. Antibodies may be an indication of past infection 
and may have a role for detecting active TB in conjunction with tuberculin 
testing or gamma-interferon assays. Nucleic Acid Amplification for TB or 
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Polymerase Chain Reaction (PCR) for MTB have been emerging as an 
important additional tool for diagnosis of TB.There is a role of PCR in 
detecting drug – resistant TB, especially rifampicin resistance. 
Culture 
Culturing MTB is the gold standard for the diagnosis of TB. 
Traditional methods like the Lownestein-Jenson medium is limited by the 
long-turnaround time. Radiometric Liquid culturing mediums (BACTEC) 
have a shorter turnaround time (1-2 weeks) and colonies can be used for 
speciation and assessing drug sensitivity (11). 
TREATMENT  
TB treatment in HIV positive patients 
There is no change in the recommendations for management of TB 
amongst HIV infected patients (12).  Standard short course chemotherapy 
delivered under direct supervision has similar sputum conversion rates as in 
the HIV negative population.  Malabsorption of anti-TB drugs is common 
amongst HIV infected patients particularly in advanced HIV disease and 
with concomitant chronic diarrhoea (13).  
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The role of rifampicin is critical in management and unless there is 
absolute contraindication  rifampicin should be used throughout the duration 
of TB treatment. This helps in preventing relapses and reduces mortality (14).  
However, the mortality on anit-tuberculous treatment (ATT) is higher 
amongst HIV infected patients that may be related to development of 
another opportunistic infection while waiting for initiation of antiretroviral 
therapy (ATT).  Once or twice weekly regimens are avoided particularly 
amongst patients with CD4<100/ µl, as these have been reported to increase 
the risk of acquired rifampicin resistance (15). 
 
The recommended duration of treatment is 6 months, extended 
treatment durations are recommended in CNS TB and in patients not 
receiving pyrizinamide in the intensive phase. The role of fluroquinolones 
(gatifloxacin and moxifloxcin) in shortening the duration of ATT is under 
investigation. 
 
There is no evidence for lower tolerability of ATT amongst HIV 
infected patients however some reports of higher incidence of hepatitis have 
been published (16).  
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Adjunctive treatment 
Concomitant Co-trimaxozole has demonstrated survival benefit 
amongst HIV infected patients initiating ATT(17) This is recommended for 
all HIV-TB co-infected patients irrespective of CD4 counts, however the 
benefit is greatest when the CD4 counts is less than 200/µl. There is lack of 
conclusive evidence of efficacy of concomitant multivitamins / 
micronutrients in the management of TB. Steroids are indicated for 
tubercular meningitis, pericardial TB, Adrenal TB and in patients with 
severe TB IRIS. The doses of steroids needs to carefully titrated as 
rifampicin increases clearance of steroids.  
 
Antiretroviral  therapy(ART) 
The important issues in concomitant use of ART and ATT are whom 
to initiate ART in the setting of active TB and what ARVs/ATT to use with 
reference to drug-drug interaction. 
The problems associated with simultaneous initiation of ART and 
ATT include the increased pill burden compromising adherence, probably 
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additive toxicities, difficulties in identifying the offending agent in cases of 
overlapping toxicities, and the development of IRIS. 
A recent randomized control trail (SAPIT) demonstrated that in HIV-
TB patients with CD4<500/µl, waiting for initiating ART until the 
completion of the maintenance phase of TB treatment  was associated with 
higher mortality (18).  The trail is on-going to look at mortality outcomes in 
patients initiating ART as soon as ATT is tolerated versus until completion 
of intensive phase of ATT. Until further evidence is available it may be 
prudent to offer ART to all HIV-TB patients with CD4 <350/µl as soon as 
ATT is tolerated (within 2 weeks) and wait for completion of the intensive 
phase in patients with higher CD4 counts.  
The major issue associated with simultaneous use of ATT and ART is 
drug reactions and drug interactions. Rifampicin (RMP) is a potent inducer 
of CyP4503A4 isoenzymes that can reduce the levels of Non-nucleoside 
reverse transcriptase inhibitors (NNRT) and protease inhibitors (Pls) which 
are substrates for this enzyme (19,20).  Sub-optimal levels of ARVs lead to 
rapid selection of drug resistance HIV causing treatment failure and clinical 
progression. Of all the ARVs only efavirenz levels is not impacted 
significantly and has excellent long term effectiveness (21). The current 
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recommended dose for EFV in patients weighting <65 kgs is 600mg hs. 
Rifabutin (RBT) is a less potent inducer of the CyP4503A4 enzyme and can 
be used with all the NNRTIs and Pls (22).  
Rifabutin is available in India and is more expensive than rifampicin. 
The efficacy of rifabutin vis a vis RMP in achieving good TB treatment 
outcomes is similar although evidence amongst HIV infected patients is 
insufficient.  
ARV Class Recommended Alternative 
 
NNRTIs 
With rifampicin 
 
With rifabutin (300 mg 
od) 
 
With rifabutin (450 mg 
od) 
 
 
 
EFV (600 mg or 800 
mg hs) 
 
NVP (200 mg bid) 
 
EFV (600 mg hs) 
 
 
NVP (200 mg bid) 
without lead-in dose 
Pl/r 
With rifampicin 
 
With rifabutin 
(150 mg q.3W) 
 
 
All pl/r contraindicated 
 
All pl/r can be used 
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TB IRIS 
Immune Reconstitution Inflammatory Syndrome (IRIS) is defined as 
occurrence or worsening of a clinical and / or laboratory parameter despite 
favourable improvement in HIV surrogate makers (CD4 counts and Plasma 
HIV viral loads) on ART. TB IRIS is the commonest form of IRIS in the 
developing world and can occur in 15-20% of patients initiating ART(23). 
Two forms of IRIS are described. 
1.Unmasking IRIS: Emergence of a sub-clinical infection within 3 
months of ART initiation. This is usually labeled as ART associated Tb and 
if the clinical presentation is predominantly inflammatory it is defined as 
unmasking IRIS. 
2.Paradoxical IRIS: Worsening of a controlled TB (on ATT) within 3 
months of ART initiation. 
The major risk factors for development of IRIS include a CD4 count 
<50/ µl at ART initiation and shorter time between diagnosis of TB               
(and ATT initiation) and initiating ART. The commonest clinical 
presentations of TB-IRIS include inflammatory abscesses, tubercular 
meningitis/tuberculomas, spinal TB, respiratory TB and TB serositis. The 
differential diagnosis for TB-IRIS include occurrence of a true OI-TB as a 
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result of low CD4 counts, failure of ATT (drug resistant TB) and toxicities 
of ATT/ART. Management of TB-IRIS is guided more by clinical situation 
rather than evidence from trails. Anti-inflammatory agents are the mainstay 
of treatment. Steroids (dose and duration depending on clinical response) are 
used in severe TB-IRIS and ART may be discontinued in life-threatening 
situation. Finally drainage/aspiration of abscesses is needed frequently for 
many patients. ATT is also recommended if there is a high index of 
suspiction for active TB. Though TB-IRIS is associated with high morbidity, 
only CNS TB has been associated with higher mortality(24). 
 
PREVENTING TB IN HIV INFECTED PATIENTS 
The best intervention for preventing the development of active TB 
amongst  HIV infected patients is ART. Studies have documented a decline 
of 80% in the incidence of TB amongst HIV infected patients on ART(25). 
The benefit associated with the use of ART is highest within 3 months of 
initiation of ART. Another intervention that has been tested for preventing 
TB is using  ATT drugs for treatment of latent tuberculous infection(26). 
Isoniazid (INH) for 9-12 months has been shown to be effective in reducing 
TB incidence amongst TT positive but not in TT negative HIV infected 
 37
patients. However INH did not have any impact on death rates in this 
cochrane review. The duration of protection of INH treatment is 2-3 years 
and the risk of development of INH resistance is low. The efficacy of INH 
treatment is further amplified with the use of concomitant ART. Secondary 
INH prophylaxis to prevent relapses has also been successful in some 
settings. One of the critical issues in initiating INH is ruling of active TB 
which can be difficult amongst HIV infected patients. 
Recently a TB vaccine (M.vaccae) when combined with INH 
treatment was shown to reduce the incidence of TB by 37% amongst HIV 
infected patients(27). 
 
MDR/XDR-TB IN THE CONTEXT OF HIV 
The association of MDR/XDR TB with HIV infection is variable, 
though it is stronger for XDR-TB(28). A significant proportion of 
MDR/XDR-TB is associated with exogenous re-infection. Thus improving 
adherence to ATT may not prevent the emergence of MDR/XDR-TB 
amongst HIV infected patients. Institutional and even community outbreaks 
have been documented and drug resistance bacilli are more infectious and 
pathogenic as compared to the drug-susceptible ones. Even when 
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appropriately treated including with ART high and rapid mortality is 
associated with XDR-TB(29).The Principles of management of MDR-TB are 
the same as in HIV negative patients. Early diagnosis (using rapid methods) 
is the mainstay. There is very limited evidence on the safety and efficacy of 
the use of second line ATT drugs along with ART. 
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                              METHODOLOGY 
PLACE:  Chest clinic and Department of Medicine, Government Stanley     
               Hospital.  
DESIGN: Observational study 
PERIOD: October 2007 to October 2009 
SAMPLE SIZE: 21 
 
INCLUSION CRITERIA: 
1. Age > 12years 
2. Patients who are HIV seropositive with features of pulmonary 
tuberculosis like fever,cough, loss of appetite and weakness. 
EXCLUSION CRITERIA: 
1. Patients who show features of Extrapulmonary tuberculosis. 
METHODS: 
                     Persons who found to become seropositive for HIV at 
Voluntary Counselling and Testing Centre were referred to Chest clinic to 
screen for the presence of tuberculosis. A detailed history of present, past, 
personal and family was elicited from these patients. They were subjected to 
general and systemwise examination with careful search for markers of 
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tuberculosis  and HIV. Basic investigations like Hemogram, Urine routine, 
Renal and Liver function tests were done.  Mantoux test, Sputum 
examination for Acid Fast Bacilli and Chest Xray were carried out according 
to there symptoms. CD4+ lymphocyte count was measured. 
  
Patients were diagnosed as pulmonary tuberculosis if, 
1. Mantoux test showed reading >5mm 
2. Sputum examination for Acid Fast Bacilli showed positive  
3. Chest Xray showed features of tuberculosis confirmed by radiologist. 
 
Those who showed  negative  for  pulmonary tuberculosis during 
initial screening were followed for the development of the same.                      
The pulmonary tuberculosis positive patients were started with 
antituberculous and antiretroviral drugs. They were followed up 
regularly and observed for drug reactions and interactions. Their 
outcome was recorded at the end of the treatment. All relevant data 
were analysed at the end of the study. 
  
Ethical committee  approval was obtained for the study. 
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RESULTS 
PREVALENCE 
Out of the 83 confirmed cases of HIV infection, 21 persons found to 
be suffering from pulmonary tuberculosis. These 21 persons formed the 
study population. 
 
The prevalence of pulmonary tuberculosis infection in HIV 
seropositive individuals was 21 out of 83 i.e. 25.3% 
 
21
83
No. of pulmonary TB HIV Patients Total HIV positive Patients
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AGE 
The Age-wise distribution of cases as follows  
Age Group Male Female 
12-20 - - 
21-30 3 (14.3%) 1 (4.8%) 
31-40 8(38.1%) 2 (9.5%) 
41-50 6(28.6%) 1(4.8%) 
>50 - - 
3
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7
8
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n
20-Dec 21-30 31-40 41-50 >50
Age Group
Male Female
 
The mean age group in Males   : 38.6 years 
The mean age group in Females : 39 years 
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SEX : 
Out of the 21 persons with both pulmonary tuberculosis and HIV, 17 
(80.10%) were males and 4 (19.04%) were females. 
 
80.10%
19.04%
Males Females
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Body Mass Index : 
Body mass index of 21 TB/HIV coinfected persons distributed as 
follows : 
BMI Males Females 
<18 9(42.8%) 2(9.5%) 
18.1-20 5 (23.8%) 1(4.8%) 
20.1-22 2(9.5%) 1(4.8%) 
>22 1(4.8%) - 
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<18 18.1-20 20.1-22 >22
Males Females
 
The average BMI for men  :  18.9 
The average BMI for women  : 18.3 
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OCCUPATION 
The following is the distribution of occupation of 21 HIV/TB 
coinfected persons  
Occupation Male Female 
Skilled Labourers 5 (23.8%) 1 (4.8%) 
Drivers 8 (38.1%) - 
Business persons         2 (9.5%) - 
House wife -            3 (14.3%) 
Others                                   2 (9.5%) - 
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Monthly income in rupees
The average monthly income is around Rs.4500/- 
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CLINICAL FINDINGS  
The following is the distribution of clinical presentations of 21 
HIV/TB coinfected individuals :- 
Clinical Presentation Number of person 
Fever 18 (85.71%) 
Cough 14 (66.66%) 
Loss of weight 21 (100%) 
Weakness 19 (90.47%) 
Skin and oral lesions 11 (52.38) 
Others 7 (33.3%) 
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SPUTUM POSITIVITY:  
Out of 21(78%) persons, 6 (22%) persons showed positive results in 
sputum for Acid-Fast bacillus examination. 
 
78%
22%
No. of person negative for sputum No. of person positive for sputum 
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MANTOUX READING :  
The distribution of  Mantoux reading of 21 HIV/TB coinfected person 
as follows : 
0
2
4
6
8
10
12
14
Upto 5mm 6-10mm >10mm
 
The mean mantoux reading is 3.3mm 
Out of 21 HIV/TB coinfected persons, 7 showed mantoux reading >5mm. 
The percentage of mantoux positivity in this context is 33.3% 
33.30%
66.70%
No. of person showing mantoux positive
No. of person negative for mantoux
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CHEST XRAY FINDINGS  
The following is the distribution of chest x-ray findings seen in 21 
HIV/TB Co-infected persons: 
Xray findings Number of person 
Upper Zone 5 (23.8%) 
Lower Zone 5 (23.8%) 
Diffuse 3 (14.3%) 
Miliary 1 (4.8%) 
Cavity 1 (4.8%) 
Hilar Lymphadenopathy 2 (9.5%) 
Pleural Effusion 1 (4.8%) 
Normal 3 (14.3%) 
  
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Upper Zone
Lower Zone
Diffuse
Miliary
Carity
Hilar
Lymphadenopathy
Pheural Effusion
Normal
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CD4+ Lymphocyte count 
The following is the distribution of CD4+ Lymphocyte count of 21 
HIV/TB coinfected persons. 
CD4+ count(Cells / µl) Male Female 
0 – 99 7 (33.3%) 1 (4.8%) 
100-199 5 (23.8%) 2 (9.5%) 
200-299           1 (4.8%)            1 (4.8%) 
300 and above 4 (19.04%)  
 
The percentage of CD4+ Lymphocyte  count <200 in our study group 
is 71.4%. The mean CD4 + count is 147 cells/microlitre. 
0
1
2
3
4
5
6
7
0 – 99 100-199 200-299 300 and
above
Male
Female
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CD4+ Lymphocyte count and Mantoux Reading 
The following is the distribution of mantoux reading in various levels 
of  CD4 + Lymphocyte count. 
 
CD4 + Count (Cells / µl) Mean Mantoux reading (in mm) 
0-99 1 
100-199 3.3 
200-299 4.5 
300 and above 7.5 
 
0
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Mean Mantoux reading (in mm)
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CD4+ Lymphocyte count and Sputum positivity 
The following is the distribution of results of sputum examination for 
acid-fast bacillus of 21 HIV/TB coinfected persons in various levels of CD4 
lymphocyte count: 
Sputum for AFB CD4 + Count  
(Cells / µl) Positive Negative 
0-99 1 (4.8%) 7 (33.3%) 
100-199 2 (9.5%) 5 (23.8%) 
200-299 1 (4.8%)           1 (4.8%) 
300 and above 2 (9.5%)           2 (9.5%) 
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 53
CD4+ Lymphocyte count and Chest Xray findings: 
The following is the distribution of chest xray patterns of 21 HIV /TB 
coinfection individuals in various levels of CD4 + cents. 
 
CD4 
counts 
Normal Hilar 
adeno-
pathy 
Upper Lower Diffuse Miliary Cavity Effu-
sion       
<200 1 
 (4.8%) 
2  
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3 
(14.3%)
1 
(4.8%) 
 1 
(4.8%) 
>200 2 
 (9.5%) 
 3 
(14.3%)
       1 
(4.8%)
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OUTCOME : 
All the 21 HIV/TB coinfected persons were started with both 
anituberculous and antiretorviral therapy and were observed clinically, 
bacteriologically and radiologically. 17 persons showed improvement and 
declared cure of pulmonary tuberculosis. 2 person did not improve and 
diagnosed as multidrug resistant tuberculsosis. 2 persons deteriorated and 
died during treatment. 
The distribution of outcome is an follows : 
Outcome No. of persons 
Cured 17 (81%) 
Deaths 2 (9.5%) 
MDR TB 2 (9.5%) 
81%
9.50%
9.50%
Cured Deaths MDR TB
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DISCUSSION 
Among 83 patients seropositive for HIV, 21 persons were found to 
develop pulmonary tuberclosis. The prevalence of pulmonary tuberculosis in 
HIV infected person was 25.3%(30). This correlates well with the estimated 
global prevalence of one third cases of  HIV positive patients coinfected 
with tuberculosis. 
 
The age groups commonly affected by pulmonary tuberculosis among 
HIV infected persons range from 20 to 50 years. The mean age for HIV/TB 
coinfection among men and women calculated to 38.6 and 39 respectively. 
This shows that the sexually active and economically productive group of 
the population is most vulnerable to HIV/TB coinfection(32). 
 
Out of 21 persons with HIV/TB coinfection, 17 were males and 4 
were females. The male to female ratio was 5:1. Males are at higher risk for 
HIV/TB coinfection(32). 
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The body mass index calculated for HIV/TB coinfected persons 
ranges from 16.6 to 22.4. The mean BMI for men and women is 18.9 and 
18.3 respectively. This correlates well with the study done  by 
 Vander Saudi MA et al.,(31) This indicates that lower BMI group is more 
prone to get pulmonary TB in HIV infection. 
 
Drivers form the most vulnerable group to acquire HIV/TB 
coinfection. This includes persons who drive autorickshaw, lorry and trailor. 
High risk behaviours such as sexual practice with commercial sex workers, 
intravenous drug abuse, alcoholism, matriutrition are seen among this group. 
Skilled labourers comprises the second largest group to have TB/HIV 
coinfection(32). 
 
The average monthly income among HIV/TB co-infected persons 
found to be around Rs.4,500 per month. Thus the lower socioeconomic 
group is at major risk for coinfection(32). 
 
The most common clinical presentation were fever, cough, weakness 
and loss of weight(39). This is comparable to the registry of AIDS at NACO 
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which also shows fever, cough, loss of weight as the commonest symptoms. 
It seems that HIV does not alter the classical symptoms of TB. 
The sputum smear positive for Acid fast bacillus in our study is 
28.6%. This is comparable to the results obtained in the earlier studies(32). In 
resources limited settings, culture for AFB is not feasible. Moreover, the 
yield of AFB in HIV infected individuals becomes low due to excretion of 
fewer organisms per milliliter. This makes very difficult to confirm 
pulmonary tuberculosis in HIV positive individuals. 
 
The percentage of tuberculin testing positivity is 33.3%. This 
increased percentage of negativity (mantoux anergy) is comparable to other 
studies(33). 
 
Atypical chest xray findings are more common in our study 
population. These included lower zone infiltrations, diffuse, miliary patterns, 
hilar lymphadenopathy and pleural effusion. This is consistent with other 
studies(34). 
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In our study, CD4 lymphocyte count of <200 cells/ µl was observed in 
15 out of 21 coinfected persons. This is consistent with the study done by 
Alpert et. al.(35) The mean CD4 + count in our study population is 148 for 
men and 146  for women. This is consistent with the study done by whalen 
et al.(36) 
 
The relationship between CD4+ count and mantoux reading, sputum 
positivity,  chest xray findings was studied in our 21 HIV/TB coinfected 
persons(37). 
         The mean mantoux reading was 2.1mm in <200cells/µl and 6.5mm in  
>200 cells/ µl. Anergy was noted in CD4 + lymphocyte count of < 200 /µl . 
 
Atypical chest xray patterns such as hilar lymphadenopathy, lower 
zone infiltration, diffuse & military patterns, effusion were noted in CD4+ 
count of <200 Cells/ µl 
CD4 + Count 
(Cells/ µl) 
Mantoux 
reading(mm) 
Sputum for 
AFB 
Chest X-ray 
<200 cells/mm3 Anergy common Negativity 
common 
Atypical findings 
common 
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During the 24 months followup of 83 HIV the cases, 21 became 
positive for pulmonary tuberculosis diagnosed by either clinical, 
bacteriological, radiological methods alone or in combination. The risk of 
getting pulmonary tuberculosis in HIV infected persons is more than that of 
general population(38). 
In our study, out of 21 HIV/TB coinfected persons, 6 fall under 
category  C2 an 15 fall under category C3. The percentage of  C2 category is 
28.5% and the percentage of C3 category is 71.5%. 
 
All the 21 persons were started with antituberculous and antiretroviral 
therapy. 19 were under Cat I and 2 under Cat II. No major adverse reactions 
were noted. Nausea and vomiting were the most common side effects. 
Among  21 cases, 17 were declared cure with antituberculous therapy in the 
form of sputum conversion, improvement in both clinical and radiological 
context. 2 persons deteriorated during treatment and died. 2 persons did not 
show improve during treatment and were referred to thoracic research 
center, chetpet, chennai and declared multidrug resistant tuberculosis. 
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CONCLUSION 
1. Pulmonary tuberculosis is more commonly seen in HIV infected 
individuals.  
2. Pulmonary tuberculosis is most commonly seen in third and fourth 
decade. 
3. Males are commonly affected that females. 
4. Body mass Index of around 18 is more prone to have pulmonary 
tuberculosis. 
5. Drivers, skilled labourers and low income group were commonly 
affected. 
6. The most common symptoms observed were fever, cough and loss of 
weight. 
7. There is increased incidence of mantoux anergy, sputum negativity,  
atypical chest xray findings were noted in HIV positive individuals 
especially in the lower CD4+ count. 
8. The risk of acquiring pulmonary tuberculosis is greater in HIV positive 
person than the general population. 
 9. The risk of drug resistant tuberculosis is increased in HIV/TB 
coinfection. 
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11. Prompt diagnosis and timely administration of ATT and ART therapy 
results in effective cure of pulmonary TB in HIV positive individuals. 
 
Unless properly managed, the negative synergy between TB and HIV 
threatens to become a major public health problem in future. Fortunately 
effective interventions are available for both; however integration of these 
interventions in clinical care and programs is critical. The emergence of 
MDR/XDR-TB is an ominous sign, control of which needs a refocus on 
hitherto neglected infection control practices apart of ensuring proper use of 
ATT. Improvements in both ATT and ART drugs is needed to shorten the 
duration of TB treatment, with no drug-drug interactions, and very minimal 
toxicities so that treatment for both diseases can be optimized. 
 
 
 
  
 
                                PROFORMA 
•      NAME : 
•      AGE : 
•      SEX : 
•      OCCUPATION : 
•      MONTHLY INCOME : 
•      Ht(cm) : 
•      Wt(kg) : 
•      BMI(kg/m2 ) : 
•      CLINICAL PRESENTATION:             
 cough/expectoration 
 fever/evening rise of temperature 
 loss of appetite/loss of weight 
 hemoptysis 
 diarrhea/others 
 
 
 
 
•     PAST Hx: 
•    DRUG ABUSE : 
•    FAMILY HISTORY : 
•    GENERAL EXAMINATION                                                                
               Built/ skeletal appearance 
                   anemia/jaundice/cyanosis/clubbing/ 
                   lymphadenopathy/pedal edema/JVP/ 
          vitamin deficiencies and      
          markers of TB & HIV  
  VITALS : Temperature/Pulse/BP/RR 
  CVS : Apical impulse/heart sounds/others 
  RS : Tracheal position/air entry/breath sounds/others 
  P/A : Organomegaly/mass/free fluid 
  CNS : ALOC/neurological deficit/meningeal signs 
 
 
 
 
 
• INVESTIGATIONS 
CBC :  TC, DC, ESR, Hb, Platelets,PS  
RBS, Urea, creatinine, electrolytes 
Liver function tests 
Urine R/e 
Sputum for AFB (3 samples) 
Mx test 
Chest X Ray 
CD4+ count 
 
 
CONSENT   
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MASTER CHART 
 
Clinical presentation 
S. 
No. Name Age Sex BMI Occupation 
Monthly 
income 
(Rs) 
Fev
-er 
Cou
-gh 
Loss 
of wt 
Weak 
ness 
Skin 
oral Others 
Past 
history 
Mx 
(mm) 
Sput-
um 
for 
AFB 
Chest 
X-ray 
CD4 
cell/ 
µl 
Clini-
cal 
stagi-
ng 
ATT 
cate-
gory 
outcome 
1              Velu 42 M 20.8 Tailor 6000 4 4 4 4 Hemo-ptysis 3 +ve Normal 88 C3 I Cured
2.              Ramesh 33 M 21.3 Mason 4500 4  4 4 4 8 Hilar 156 C3 I Cured
3.       Vijay 27 M 17.6 Autodriver 3500 4 4 4 4 4   nil -ve Diffuse 40 C3 I  MDR TB 
4.              Alimudheen 38 M 17.5 Shopkeeper 5000 4 4 4 4  nil -ve Lower 38 C3 I MDR-TB
5.             Nagaraj 37 M 17.7 Harbour Cooly 3000 4  4 4  PT 7 Upper  320 C2 II Cured
6.          Latha 30 F 19.1 Skilled Labourer 2500 4 4 4 4 4 6 +ve Diffuse  161 C3 I Cured
7.             Raja 50 M 21.9 Lorry Driver 5500 4 4 4 4  5 -ve Upper 327 C2 I Cured
8.       Pandurangan 46 M 18.8 Auto Driver 4800 4  4 4   IV drug abuse  Nil  Hilar 136 C3 I Cured 
9.               Kiruba 38 F 16.6 Housewife 6000 4 4 4 4 4 Diarrhe-a Nil -ve Lower 28 C3 I Died
10.              Kannan 46 M 18.0 Auto driver 3000 4 4 4 4 4 Abd- pain 
IV drug 
abuse 5 -ve Diffuse 58 C3 I Cured
11.           Damodaran 36 M 19.5 Trailor Driver 4500 4 4 4  4 
Abd- 
pain 7 +ve Normal 313 C2 I Cured
12.        4 4        Narasimhan 38 M 22.4 Lorry Driver 5000 10 +ve Cavity 365 C2 I Cured
13.       Elumalai 38 M 16.9 Taxi Driver 3500 4 4 4 4 4 Diarroea PT Nil  -ve Miliary  24 C3 II Died 
14.               Kandhan 38 M 17.7 Vendor 2000 4  4 4 4 4 Lower 118 C3 I Cured
15.               Munusami 45 M 17.5 Business 6000 4 4 4 4 4 Abd- pain Nil -ve Lower 13 C3 I Cured
16.               Babu 39 M 18.0 Lorry Driver 4500 4 4 4 4  Scrofula Nil +ve Effusion 114 C3 I Cured
17.               Lingam 48 M 17.6 Mason 4000 4  4 4 4 Abd- pain Nil Lower 13 C3 I Cured
18.              Mani 28 M 19.0 Business 6000 4  4 4  Nil Upper 182 C3 I Cured
19.             Jayalakshmi 50 F 20.3 House wife 2000 4 4 4 4  6 -ve Upper 188 C3 I Cured
20.            Kalaiselvi 38 F 17.6 Housewife 3200 4 4 4 4  Nil -ve Upper 207 C2 I Cured
21.      4 4 4 4       Selvam 27 M 19.3 Scrap cleaner 2000 
Diarrhe
a 9 +ve Normal 213 C2 I Cured
 
 
